Mannitol 0.54% / Sorbitol 2.7% irrigation solution 2litre bottles
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Mannitol + Sorbitol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Mannitol + Sorbitol on the MHRA register
Purisole irrigation solution 2litre Flowfusor bottles
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 1940–2026
Showing the 50 most relevant studies, sorted by most relevant.
H. Ohrem, Eva Schornick, Adela Kalivoda, et al.
Pharmaceutical Development and Technology, 2014
Hany Shawkat, M. Westwood, A. Mortimer
Continuing Education in Anaesthesia, Critical Care & Pain, 2012
S. Twetman
Evidence-Based Dentistry, 2009
Heianza Y, Rood JC, Champagne CM, et al.
2026
BackgroundHigh circulating concentrations of sugar alcohols (polyols) have recently been linked to increased risks of cardiovascular events.ObjectivesWe investigated whether temporal changes in plasma concentrations of erythritol and other isomeric polyols (arabitol/xylitol and mannitol/sorbitol) in response to weight-loss dietary interventions were associated with improvements in atherosclerotic cardiovascular disease (ASCVD) risk estimates and atherogenic lipid profiles among adults with overweight or obesity.MethodsWe performed an observational analysis using data from adults with overweight or obesity who participated in the 2-y Preventing Overweight Using Novel Dietary Strategies trial. Plasma erythritol, arabitol/xylitol, and mannitol/sorbitol were measured at baseline (n = 802, n = 805, and n = 803, respectively) and at 6 mo. Temporal changes were calculated among participants with measurements at both time points (n = 664, n = 669, and n = 668, respectively). The primary outcome was the 10-y ASCVD risk estimated using the validated pooled cohort equations. Two-year changes in cholesterol in lipoprotein subfractions with or without apolipoprotein C-III (apoC-III) were analyzed as secondary outcomes.ResultsHigher baseline levels of erythritol [β per 1 standard deviation (SD): 1.1%; standard error (SE): 0.2%], arabitol/xylitol (β: 1.3%; SE: 0.2%), and mannitol/sorbitol (β: 1.1%; SE: 0.2%) were associated with higher ASCVD risk estimates (P ConclusionsDeclines in plasma erythritol concentrations in response to weight-loss dietary interventions were associated with improvements in ASCVD risk estimates and atherogenic lipid subtypes containing apoC-III. These findings highlight the potential role of changes in plasma erythritol concentrations in relation to improvements in cardiometabolic risk among adults with overweight or obesity. This trial was registered at clinicaltrials.gov as NCT00072995.
Abstract licence: CC BY-NC-ND
B. Shen, S. Hohmann, R. Jensen, et al.
Plant physiology, 1999
J STOOP, J WILLIAMSON, D MASONPHARR
Trends in Plant Science, 1996
H. Valizadeh, A. Nokhodchi, Nahid Qarakhani, et al.
Drug Development and Industrial Pharmacy, 2004
Helmut Franke, Hans-Joachim Galla, Carsten T Beuckmann
Brain Research, 1999
W. Smith, Norma Finkelstein, H. W. Smith
Journal of Biological Chemistry, 1940
Xing-Guang Zhang, L. Durndell, M. Isaacs, et al.
ACS Catalysis, 2016
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.